Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Ruxolitinib

2

XVII.b Opportunistic pulmonary/systemic infections

1
Last update : 26/10/2014
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Ruxolitinib dicontinuation/withdrawal
1

Publications

Ruxolitinib-associated infections: A systematic review and meta-analysis.
American journal of hematology 2018 Mar;93;339-347 2018 Mar
Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib.
Case reports in hematology 2016;2016;2389038 2016
An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.
Chest 2013 May;143;1478-1479 2013 May

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies